The On-Demand content consists of slides narrated by the course faculty via video and provides you with team-based expert guidance on managing GI patients through case-based learning. The course is designed to provide the highest quality, GI-specific education available to APPs and to cater to both experienced providers and those new to the field. The On-Demand course will provide self-paced access to sessions in upper and lower GI disorders including EoE, IBD cases and IBD pharmacology, IBS, CRC screening, liver and pancreatic disease.
If you already enrolled or purchased this course, please log into My Courses and launch "2022 Principles of GI: On-Demand"
Course directors
Kian Keyashian, MD
Jody Weckwerth, PA-C
Course directors elect
Gregory Sayuk, MD, MPH, AGAF
Ashley Salamone, MSN, CRNP
| Pricing |
|---|
| AGA Member |
| $250 |
| Nonmember |
| $450 |
Disclosures container
| Presentation Topic/Title | Learning Objectives |
|---|---|
| Session 1 | |
| Disorders of Brain-Gut Interaction: Commonalities in Management |
Define DGBI pathophysiology and best management procedures, with focus on neuromodulators and central-based therapy |
| Treatment of Irritable Bowel Syndrome: Medications |
Identify cost-effective and pragmatic approach to diagnosing and treating IBS (FODMAPS diet, pharmacologic therapies, etc.) |
| Practical Nutrition for GI disorders and Complementary Alternative Treatments with Nutrition |
Appraise the evidence and recommendations for specific nutritional and complementary therapies in gastroenterology, with a focus on IBS |
| Gas and Bloating: Diagnostics and Treatment | Examine the presentation and management of gas and bloating and practical treatment options |
| Session 2 | |
| Approaching Diarrhea and Fecal Incontinence |
Discuss the evaluation and management of diarrhea Review appropriate diagnostic evaluation of fecal incontinence |
| Barrett's Esophagus | Review the risk factors for Barrett's esophagus and identify recommended screening practices and treatment options |
| Diving into Dysphagia | Outline pragmatic approach to the evaluation of dysphagia including the appropriate use of endoscopy, manometry, and barium swallow |
| GERD | Describe the diagnostic evaluation and management of GERD and refractory GERD, including anti-reflux surgery |
| Session 3 - Breakouts | |
| Breakout A | |
| Esophageal Manometry and pH Studies | Discuss HRM interpretation for the evaluation and treatment of esophageal motility patterns; identify situations in which pH testing could help in diagnosis and treatment of esophageal symptoms |
| Liver Test/Blood Test Abnormalities | Contrast acute and chronic etiologies of liver test abnormalities, provide a pragmatic approach to evaluation |
| Liver Lesions: What Imaging to Order and When |
Review best practices for imaging orders, providing case-based rationale, and interpretation of findings, in the setting of liver lesions |
| Breakout B | |
| Chronic Pancreatitis | Describe diagnosis of chronic pancreatitis, its long-term complications, and non-pharmacologic and pharmacologic treatment options, particularly efficacy, dosing and side effects and therapies under investigation |
| Pancreatic Cysts | Discuss differential diagnosis of pancreatic cystic lesions, available imaging modalities, and recent practice management guidelines |
| Updates in Colon Cancer Screening: Guidelines and Surveillance |
Appraise consensus definitions of genetic syndromes associated with colorectal cancer, including FAP and HNPCC, when to suspect them, when to refer, and screening and surveillance protocols |
| Session 4 - Liver | |
| Management of Complications of Cirrhosis | Compare and contrast modalities to diagnose cirrhosis (including non-invasive tests), when to refer to a transplant center and current issues in transplantation |
| The A, B & C's of Hepatitis | Discuss relevant data and procedures regarding HAV Review the diagnosis and management of chronic Hepatitis B infection Describe updates on emerging therapies for management of |
| Fatty Liver | Describe the epidemiology and pathophysiology of nonalcoholic fatty liver Review the diagnostic tests used in nonalcoholic fatty liver disease Explain the therapeutics use in nonalcoholic fatty liver disease |
| Autoimmune Liver Diseases: PBC, PSC, AIH |
Assess presentation and treatment of autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis, including self-care regimens and pharmacological management |
| Session 4 - IBD | |
| Inflammatory Bowel Disease - New Dx: Presentation and Diagnostics |
Describe the epidemiology and presentation of inflammatory bowel disease, with a focus on relevant diagnostics |
| Special Populations (Transitions, Elderly, Pregnancy) |
Explore the management of inflammatory bowel disease in special populations including any differences in drug level/antibody monitoring and combination therapy |
| Nutrition in IBD | Review guidelines for the role of nutrition in inflammatory bowel disease, with some discussion of supporting evidence |
| Inpatient Management of IBD | Evaluate case-based challenges in the inpatient management of IBD, outlining UC protocols and complications related to CD |
| IBD Pharmacology | Describe guidelines-based pharmacological management of IBD, including use of TDM, Biosimilars, and new therapies |
| Session 5 | |
| The 4 C's of Biliary Disorders: Cholithiasis through Cholangitis |
Summarize various biliary disorders, with a focus on presentation and best practices with case-based evidence |
| Bariatric Complications and Obesity Management |
Review the epidemiology and management of complications of bariatric surgery Describe the epidemiology of obesity, its associated |
| Gastroparesis: Management in 2022 | Define and diagnose of Gastroparesis (including medications that affect test results) and non-pharmacologic and pharmacologic treatment options, particularly efficacy, dosing and side effects and therapies under investigation |
| Celiac: Diagnosis and Nutrition | Discuss the presentation, management, and complications of Celiac disease including the spectrum of gluten-related GI disorders |
| Session 6 - Tracks | |
| Early Career Track | |
| Constipation: Let’s Work It Out | Examine the evaluation and management of constipation |
| Feeding Tube 101 | Review guidelines and best practices for usage of feeding tubes |
| Iron Deficiency Anemia with Capsule Endoscopy |
Explain presentation, diagnosis, and management of iron deficiency anemia Review small bowel capsule endoscopy indications, Explore the APP role in small bowel capsule endoscopy |
| Advanced APP Track | |
| Eosinophilic Esophagitis | Review updated diagnostic criteria, recent guidelines on the management, and novel treatment approaches for eosinophilic esophagitis |
| Benign Perianal Pathology | Distinguish common perianal diseases and emerging treatment options via case-based best practices |
| c. difficile and FMT | Summarize current management protocols for c. difficile and outcomes considerations in fecal matter transplantation |
Accreditation and Designation Statement
The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AGA Institute designates this enduring material for a maximum of 19.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
AAPA
The American Academy of Physician Assistants accepts certificates of participation for educational activities for AMA PRA Category 1 Credits™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 19.5 hours of Category 1 credit for completing this course.
CME expiration date: Oct 31, 2024
Financial disclosures (PDF)